The clinicopathological features of patients fulfilling the revised Bethesda guidelines include young age, high rate of right colon cancer involvement, poor differentiation, MMR protein under-expression (hMLH1 and hMSH2), and MSI-H. This evidence concerns the gene MLH1 and malignant colon neoplasm.